BioCryst Pharmaceuticals' stock narrative shifted recently as analysts adjusted their fair value estimate from $20.27 to $19.73 per share. This modest decrease follows the company’s acquisition of ...
Federal National Mortgage Association (FNMA) drew attention as it delivered its third quarter earnings report, revealing a decrease in net income from a year earlier. At the same time, a senior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback